Incyte (INCY) Non-Current Assets (2010 - 2026)
Incyte posted quarterly Non-Current Assets of $1.9 billion for Q1 2026, down 17.27% year-on-year from $2.2 billion in Q1 2025, and down 4.1% on a QoQ basis from $1.9 billion in Q4 2025.
Incyte (INCY) has 17 years of Non-Current Assets data on file, last reported at $1.9 billion in Q1 2026.
- For the quarter ending Q1 2026, Non-Current Assets fell 17.27% year-over-year to $1.9 billion; the trailing twelve-month figure through Mar 2026 stood at $8.0 billion (down 8.31% YoY), and the FY2025 full-year result was $1.9 billion, down 12.3% from the prior year.
- Non-Current Assets for Q1 2026 stood at $1.9 billion, down from $1.9 billion in the prior quarter.
- Across five years, Non-Current Assets topped out at $2.3 billion in Q1 2024 and bottomed at $1.7 billion in Q3 2022.
- The 5-year median for Non-Current Assets is $2.0 billion (2023), against an average of $2.0 billion.
- The widest annual swing landed in 2022, when Non-Current Assets jumped 45.78%; it then declined 17.27% in 2026.
- A 5-year view of Non-Current Assets shows it stood at $1.7 billion in 2022, then increased by 22.23% to $2.1 billion in 2023, then gained by 3.21% to $2.2 billion in 2024, then fell by 12.3% to $1.9 billion in 2025, then fell by 4.1% to $1.9 billion in 2026.
- The last three Non-Current Assets figures came in at $1.9 billion (Q1 2026), $1.9 billion (Q4 2025), and $2.1 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 4.56 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | 62,953.78 |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 486.60 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | 5.83 Mn |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 30.30 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 14.75 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 22.66 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 910.24 Mn |
| 10 | Incyte | 19.28 Bn | 15.27 Bn | 1.17 Bn | 1.85 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.85 Bn |
| Dec 31, 2025 | 1.93 Bn |
| Sep 30, 2025 | 2.05 Bn |
| Jun 30, 2025 | 2.18 Bn |
| Mar 31, 2025 | 2.24 Bn |
| Dec 31, 2024 | 2.21 Bn |
| Sep 30, 2024 | 2.20 Bn |
| Jun 30, 2024 | 2.09 Bn |
| Mar 31, 2024 | 2.29 Bn |
| Dec 31, 2023 | 2.14 Bn |
| Sep 30, 2023 | 1.99 Bn |
| Jun 30, 2023 | 1.94 Bn |
| Mar 31, 2023 | 1.83 Bn |
| Dec 31, 2022 | 1.75 Bn |
| Sep 30, 2022 | 1.69 Bn |
| Jun 30, 2022 | 1.69 Bn |
| Mar 31, 2022 | 1.77 Bn |
| Dec 31, 2021 | 1.81 Bn |
| Sep 30, 2021 | 1.28 Bn |
| Jun 30, 2021 | 1.28 Bn |
| Mar 31, 2021 | 1.21 Bn |
| Dec 31, 2020 | 1.20 Bn |
| Sep 30, 2020 | 1.15 Bn |
| Jun 30, 2020 | 1.13 Bn |
| Mar 31, 2020 | 1.04 Bn |
| Dec 31, 2019 | 945.26 Mn |
| Sep 30, 2019 | 67.60 Mn |
| Jun 30, 2019 | 889.01 Mn |
| Mar 31, 2019 | 849.66 Mn |
| Dec 31, 2018 | 61.60 Mn |
| Sep 30, 2018 | 62.80 Mn |
| Jun 30, 2018 | 799.07 Mn |
| Mar 31, 2018 | 836.46 Mn |
| Dec 31, 2017 | 64.80 Mn |
| Sep 30, 2017 | 832.98 Mn |
| Jun 30, 2017 | 794.64 Mn |
| Mar 31, 2017 | 788.17 Mn |
| Dec 31, 2016 | 644.42 Mn |
| Sep 30, 2016 | 65.30 Mn |
| Jun 30, 2016 | 625.85 Mn |
| Mar 31, 2016 | 168.36 Mn |
| Dec 31, 2015 | 165.07 Mn |
| Sep 30, 2015 | 33.70 Mn |
| Jun 30, 2015 | 197.35 Mn |
| Mar 31, 2015 | 170.48 Mn |
| Dec 31, 2014 | 116.90 Mn |
| Sep 30, 2014 | 122.65 Mn |
| Jun 30, 2014 | 101.96 Mn |
| Mar 31, 2014 | 85.66 Mn |
| Dec 31, 2013 | 73.77 Mn |
| Sep 30, 2013 | 23.66 Mn |
| Jun 30, 2013 | 20.85 Mn |
| Mar 31, 2013 | 21.17 Mn |
| Dec 31, 2012 | 20.91 Mn |
| Sep 30, 2012 | 17.81 Mn |
| Jun 30, 2012 | 17.81 Mn |
| Mar 31, 2012 | 17.43 Mn |
| Dec 31, 2011 | 18.18 Mn |
| Sep 30, 2011 | 24.81 Mn |
| Jun 30, 2011 | 24.74 Mn |
| Mar 31, 2011 | 33.64 Mn |
| Dec 31, 2010 | 34.13 Mn |